Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Sutro Biopharma (United States) | Researchclopedia

Back to institutions

Sutro Biopharma (United States)

South San Francisco, Californiacompany

127

Works

23,625

Citations

69

h-index

Top Research Topics

Monoclonal and Polyclonal Antibodies Research HER2/EGFR in Cancer Research CAR-T cell therapy research

Top Researchers

Christopher J L Murray Institute for Health Metrics and Evaluation

1,007 works550,586 citationsh-index: 256

Recent Research

956 Next-generation immunostimulatory antibody-drug conjugates (iADCs) combine tumor cell killing with immune activation to induce durable antitumor immunity

Gang Yin,Robert Yuan,et al.

20250 citations

Ovarian cancer diagnosis and treatment

Lymphoma Diagnosis and Treatment

RNA and protein synthesis mechanisms

Protein purification and stability

Radiopharmaceutical Chemistry and Applications

Click Chemistry and Applications

Viral Infectious Diseases and Gene Expression in Insects

Lung Cancer Treatments and Mutations

Chemical Synthesis and Analysis

J. Jack Lee Chonnam National University

2,763 works90,793 citationsh-index: 146

John J. Fung Royal Free London NHS Foundation Trust

1,709 works62,937 citationsh-index: 123

Li Liu Kunming University of Science and Technology

908 works33,417 citationsh-index: 74

Hans‐Peter Gerber Sutro Biopharma (United States)

240 works27,840 citationsh-index: 58

Jennifer S. Smith

555 works25,703 citationsh-index: 73

Efficacy and safety of luveltamab tazevibulin in patients with recurrent platinum-resistant ovarian cancer: Results from the dose-optimization stage of the REFRαME-O1 (GOG-3086, ENGOT-79ov, and APGOT-OV9) phase II/III study

Jung-Yun Lee,Ana Oaknin,et al.

20252 citations

A phase 1/2, open-label study evaluating the efficacy, safety, and pharmacokinetics of luveltamab tazevibulin in infants and children < 12 years of age with <i>CBFA2T3::GLIS2</i> acute myeloid leukemia.

Sarah K. Tasian,Himalee S. Sabnis,et al.

20250 citations

Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations

Miao Wen,Abigail Yu,et al.

202514 citations

PF-08046032: A Novel, Investigational CD25-Directed Antibody–Drug Conjugate Optimized for Selective Depletion of Regulatory T Cells in Advanced Malignant Tumors

Sherif Abdelhamed,Xinqun Zhang,et al.

20255 citations

The Anti-FRα Antibody–Drug Conjugate Luveltamab Tazevibulin Demonstrates Efficacy in Non–Small Cell Lung Cancer Preclinical Models and Induces Immunogenic Cell Death

Robert Yuan,Andrew McGeehan,et al.

20254 citations